Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats

European Journal of Pharmaceutical Sciences

Volumn 6, Issue 2, 1998, Pages 93-98

  Blotnik, Simcha ^a   Bergman, Felix ^a   Bialer, Meir ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Antiepileptic activity; Brain and liver distribution; Cyclopropane analogues; Pharmacokinetics; Valpromide

Indexed keywords

VALPROMIDE;

ANIMAL EXPERIMENT; ANTICONVULSANT THERAPY; ARTICLE; BIOTRANSFORMATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; EPILEPSY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

AMIDES; ANIMALS; ANTICONVULSANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BRAIN; CYCLOPROPANES; HALF-LIFE; LIVER; MALE; METABOLIC CLEARANCE RATE; RATS;

EID: 0032055565     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(97)00081-X     Document Type: Article

References (28)

1. Altman, P.L., Dittmer, D.S., 1974. Biological Data Book, 2nd ed., vol. 3, Federation of American Societies for Experimental Biology, Bethesda, MD, pp. 1702-1710.
2. Bialer M. Clinical pharmacology of valpromide. Clin. Pharmacokinet. 2:1991;114-122.
3. Bialer M., Hadad S., Kadry B., Abdul-Hai A., Haj-Yehia A., Sterling J., Herzig Y., Yagen B. Pharmacokinetic analysis and antiepileptic activity of tetramethylcyclopropane analogues of valpromide. Pharm. Res. 13:1996;284-289.
4. Blotnik S., Bergman F., Bialer M. Disposition of valpromide, valproic acid and valnoctamide in the brain, liver, plasma and urine of rats. Drug Metab. Dispos. 241:1996;560-564.
5. Benet L.S., Galeazzi R.L. Noncompartmental determination of steady-state volume of distribution. J. Pharm. Sci. 68:1979;1071-1074.
6. Gibaldi, M., Perrier, D., 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, New York, pp. 445-449.
7. Haberer L.J., Pollack G.M. Disposition and protein binding of valproic acid in the developing rat. Drug Metab. Dispos. 22:1994;113-119.
8. Haj-Yehia A., Bialer M. Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity. Pharm. Res. 6:1989;682-689.
9. Haj-Yehia A., Bialer M. Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity. J. Pharm. Sci. 79:1990;719-724.
10. Haj-Yehia A., Hadad S., Bialer M. Pharmacokinetic analysis of the structural requirements for forming 'stable' analogues of valpromide. Pharm. Res. 9:1992;1058-1063.
11. Kaplan S.A., Jack M.L., Cotler S., Alexander K. Utilization of area under the curve to elucidate the disposition of an extensively biotransformed drug. J. Pharmacokinet. Biopharm. 1:1973;201-216.
12. Kerr B.M., Rettie A.N., Eddy A.C., Loiseau P., Guyot M., Wilensky A.J., Levy R.H. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: In vitro/in vivo correlation. Clin. Pharmacol. Ther. 46:1989;82-93.
13. Kerr B.M., Levy R.H. Unsubstituted amides: new class of potent inhibitors of human microsomal epoxide hydrolase. Drug Metab. Dispos. 18:1990;540-542.
14. Konig St. A., Siemes H., Blasker F., Boenigk E., Grop-Selbeck G., Hanefeld F., Haas N., Kohler B., Koelfen W., Krointhenberg R., Kurek E., Lenard H.G., Penin H., Penzien J.M., Schmumke W., Schultze C., Stephan U., Stute M., Traus M., Wienmann H.M., Scheffner D. Severe hepatotoxicity during valproate therapy: An update and report of eight new fatalities. Epilepsia. 35:1994;1005-1015.
15. Levy, R.H., Penry, J.K., 1991. Idiosyncratic Reactions to Valproate: Clinical Risk Patterns and Mechanism of Toxicity. Raven Press, New York.
16. Levy, R.H., Shen, P.D., 1995. Valproate: absorption; distribution and excretion. In: Levy, R.H., Mattson, R.H., Meldrum, B.S. (Eds.), Antiepileptic Drugs, 4th ed., and other chapters on valproate therein. Raven Press, New York, pp. 605-620.
17. Monaco, F., Sechi, G., 1991. The brain distribution of old and new antiepileptic drugs. In: Pisani, F., Perucca, E., Avanzini, G., Richens, A. (Eds.), New Antiepileptic Drugs. Elsevier, Amsterdam, pp. 57-65.
18. Nadler, V., Kloog, Y., Sokolovsky, 1988. 1-Aminocyclopropane-1-carboxylic Acid (ACC) minics and effects of glycine in the NMDA receptor ion channel. Eur. J. Pharmacol. 157, 115-116.
19. Nau, H., Hendrickx, A.G., 1987. Valproic Acid Teratogenesis. ISI Atlas Sci. Pharmacol. pp. 52-56.
20. Nau H., Hauck E.S., Ehlers K. Valproic acid induced neural tube defects in mouse and humans: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanism. Pharmacol. Toxicol. 69:1991;310-321.
21. Pisani P., Haj-Yehia A., Fazio A., Asteri C., Oteri G., Perucca E., Kretz D.L., Levy R.H., Bialer M. Carbamazepine-valnoctamide interaction in epileptic patients: in vitro/in vivo correlation. Epilepsia. 34:1993;954-959.
22. Porter R.J., Ceregino J.J., Gladding G.D., Hessie B.J., Kupferberg H.J., Scoville B., White B.G. Antiepileptic drug development program. Cliv. Clin. Q. 51:1984;293-305.
23. Rowland, M., Tozer, T., 1995. Clinical Pharmacokinetics, 3rd ed. Williams & Wilkins, Baltimore, pp. 158-163.
24. Trullas R., Folio T., Young A., Miller R., Boje K., Skolnik P. 1-Aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. Eur. J. Pharmacol. 203:1991;379-385.
25. Wieser H.G. Comparison of valproate concentrations in human plasma, CSF and brain distribution after administration of different formulations of valproate and valpromide. Epilepsy Res. 9:1991;154-159.
26. Wilkinson G.R., Shand D.G. A physiological approach to hepatic clearance. Clin. Pharmacol. Ther. 18:1975;377-389.
27. Yamaoka, K., 1986. Methods for Pharmacokinetic Analysis for Personal Computer, 2nd ed. Nanko-D, Tokyo, pp. 145-175.
28. Yamaoka K., Nakagawa T., Uno T. Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 6:1977;547-558.